PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers

The proprotein convertase subtilisin/kexin type 9 inhibitors or monoclonal antibodies likely represent the greatest advance in lipid management in 30 years. In 2015 the US Food and Drug Administration approved both alirocumab and evolocumab for high‐risk patients with familial hypercholesterolemia (...

Descripción completa

Detalles Bibliográficos
Autores principales: Baum, Seth J., Toth, Peter P., Underberg, James A., Jellinger, Paul, Ross, Joyce, Wilemon, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2017
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412679/
https://www.ncbi.nlm.nih.gov/pubmed/28328015
http://dx.doi.org/10.1002/clc.22713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412679/
https://www.ncbi.nlm.nih.gov/pubmed/28328015
http://dx.doi.org/10.1002/clc.22713

Ejemplares similares